Literature DB >> 2128320

Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement.

W Boogerd1, W W ten Bokkel Huinink, O Dalesio, W J Hoppenbrouwers, J J van der Sande.   

Abstract

A prospective study was performed in patients treated with cisplatin to evaluate the occurrence and degree of central, peripheral and autonomic neuropathy and to determine the most accurate method to study this neuropathy. Twelve patients were examined before, during and after treatment. Evaluation included neurologic examination, conventional nerve conduction studies of the median and peroneal nerves and short latency somatosensory evoked potentials (SSER) after median and tibial nerve stimulation. Valsalva maneuvers before and during treatment were performed in 11 patients. Symptoms of peripheral neuropathy paralleled clinical signs. Conventional nerve conduction studies did not seem to be more accurate than clinical examination in determining peripheral neuropathy. SSER appeared to be the most sensitive method for the detection of peripheral nerve impairment. A slowing of central conduction velocity occurred after cumulative doses of 200-400 mg/m2 as measured by SSER. In two patients also some involvement of the autonomic nerves was suggested.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2128320     DOI: 10.1007/bf02341156

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  26 in total

1.  Polyneuropathy induced by cisplatin.

Authors:  B W Ongerboer de Visser; G Tiessens
Journal:  Prog Exp Tumor Res       Date:  1985

2.  Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer.

Authors:  R Eeles; D M Tait; M J Peckham
Journal:  Cancer Treat Rep       Date:  1986-07

3.  Cisplatin.

Authors: 
Journal:  Lancet       Date:  1982-02-13       Impact factor: 79.321

4.  Cisplatin neuropathy with Lhermitte's sign.

Authors:  J Dewar; H Lunt; D A Abernethy; P Dady; L F Haas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-01       Impact factor: 10.154

5.  Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer.

Authors:  R G van der Hoop; C J Vecht; M E van der Burg; A Elderson; W Boogerd; J J Heimans; E P Vries; J C van Houwelingen; F G Jennekens; W H Gispen
Journal:  N Engl J Med       Date:  1990-01-11       Impact factor: 91.245

6.  Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatment.

Authors:  D Hadley; H W Herr
Journal:  Cancer       Date:  1979-12       Impact factor: 6.860

7.  Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies.

Authors:  S W Thompson; L E Davis; M Kornfeld; R D Hilgers; J C Standefer
Journal:  Cancer       Date:  1984-10-01       Impact factor: 6.860

8.  Cisplatin-induced autonomic neuropathy.

Authors:  C S Rosenfeld; L E Broder
Journal:  Cancer Treat Rep       Date:  1984-04

9.  Neurotoxic effects of cisplatin therapy.

Authors:  T J Walsh; A W Clark; I M Parhad; W R Green
Journal:  Arch Neurol       Date:  1982-11

10.  The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry.

Authors:  K Tomiwa; C Nolan; J B Cavanagh
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

View more
  18 in total

1.  Cisplatin-induced autonomic neuropathy: does it really exist?

Authors:  W P Vandertop; W B de Vries; N C Notermans; M J Nijsen; D J de Wildt; C A Tulleken; W H Gispen
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

2.  SIRT2 protects peripheral neurons from cisplatin-induced injury by enhancing nucleotide excision repair.

Authors:  Manchao Zhang; Wuying Du; Scarlett Acklin; Shengkai Jin; Fen Xia
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 3.  Cardiovascular Autonomic Dysfunction in Patients with Cancer.

Authors:  Ben G T Coumbe; John D Groarke
Journal:  Curr Cardiol Rep       Date:  2018-07-03       Impact factor: 2.931

Review 4.  Chemotherapy-induced peripheral neuropathies in hematological malignancies.

Authors:  Joost Louis Marie Jongen; Annemiek Broijl; Pieter Sonneveld
Journal:  J Neurooncol       Date:  2014-10-19       Impact factor: 4.130

5.  Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione.

Authors:  G Bogliun; L Marzorati; G Cavaletti; L Frattola
Journal:  Ital J Neurol Sci       Date:  1992-11

Review 6.  Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.

Authors:  Carla C P Verstappen; Jan J Heimans; Klaas Hoekman; Tjeerd J Postma
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy.

Authors:  Juan P Cata; Han-Rong Weng; Patrick M Dougherty
Journal:  Brain Res       Date:  2008-07-15       Impact factor: 3.252

9.  Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats.

Authors:  G Cavaletti; G Tredici; P Marmiroli; M G Petruccioli; I Barajon; D Fabbrica
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

10.  Chemotherapy-induced gut toxicity and pain: involvement of TLRs.

Authors:  Rachel J Gibson; Janet K Coller; Hannah R Wardill; Mark R Hutchinson; Scott Smid; Joanne M Bowen
Journal:  Support Care Cancer       Date:  2015-11-19       Impact factor: 3.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.